Mylan Inc

MYL-Q

NASDAQ:MYL

15.86
0.00 (0.00%)
Mylan N.V. is an American global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and global headquarters in Canonsburg, Pennsylvania, US.
More at Wikipedia

Analysis and Opinions about MYL-Q

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
August 10, 2017

TEVA-N vs. MYL-Q. He does not like either at these prices. They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals. The FDA is going to alleviate the delays on getting new drugs to market. He wants to be in pharmas that have innovation. He is concerned about how their business model will fair over the next 5 years.

Show full opinionHide full opinion
Mylan Inc (MYL-Q)
August 10, 2017

TEVA-N vs. MYL-Q. He does not like either at these prices. They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals. The FDA is going to alleviate the delays on getting new drugs to market. He wants to be in pharmas that have innovation. He is concerned about how their business model will fair over the next 5 years.

PAST TOP PICK
PAST TOP PICK
February 22, 2017

(A Top Pick Feb 8/16. Down 16.58%.) Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). Unfortunately both stocks came down.

Show full opinionHide full opinion
Mylan Inc (MYL-Q)
February 22, 2017

(A Top Pick Feb 8/16. Down 16.58%.) Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). Unfortunately both stocks came down.

HOLD
HOLD
January 30, 2017

Epi Pens. They are very expensive, $600 each. They then offered a $300 generic version. There are now competitors, but they own 90% of the market place. The stock took a bit of a hit, but she still likes it and thinks they will keep market share even if prices come down a bit for Epi Pens.

Show full opinionHide full opinion
Mylan Inc (MYL-Q)
January 30, 2017

Epi Pens. They are very expensive, $600 each. They then offered a $300 generic version. There are now competitors, but they own 90% of the market place. The stock took a bit of a hit, but she still likes it and thinks they will keep market share even if prices come down a bit for Epi Pens.

DON'T BUY
DON'T BUY
January 30, 2017

People really hate this, and unfortunately it has become one of the poster children of aggressive drug pricing, high compensation of the C suite, the EpiPen debacle, and kind of a lacklustre performance. Thinks this is going to be under a lot of pressure. He would suggest that you switch into Celgene (CELG-Q).

Show full opinionHide full opinion
Mylan Inc (MYL-Q)
January 30, 2017

People really hate this, and unfortunately it has become one of the poster children of aggressive drug pricing, high compensation of the C suite, the EpiPen debacle, and kind of a lacklustre performance. Thinks this is going to be under a lot of pressure. He would suggest that you switch into Celgene (CELG-Q).

PAST TOP PICK
PAST TOP PICK
December 29, 2016

(A Top Pick Feb 8/16. Down 25.9%.) Long. (A Pairs trade with Valeant Pharmaceuticals (VRX-T).)

Show full opinionHide full opinion
Mylan Inc (MYL-Q)
December 29, 2016

(A Top Pick Feb 8/16. Down 25.9%.) Long. (A Pairs trade with Valeant Pharmaceuticals (VRX-T).)

BUY
BUY
December 23, 2016

They jacked up the price of the EpiPen and it gave a whole credibility issue problem to the company and brought it under some pressure. Healthcare and technology are those things that are going to grow in almost any market environment over the next number of years. This company is pretty well positioned. They argued their case effectively.

Show full opinionHide full opinion
Mylan Inc (MYL-Q)
December 23, 2016

They jacked up the price of the EpiPen and it gave a whole credibility issue problem to the company and brought it under some pressure. Healthcare and technology are those things that are going to grow in almost any market environment over the next number of years. This company is pretty well positioned. They argued their case effectively.

PAST TOP PICK
PAST TOP PICK
October 4, 2016

(An update from Jerome!) (A Top Pick Feb 8/16.) Long. He covered this on Aug 25/16. This is not a name he would probably go back to.

Show full opinionHide full opinion
Mylan Inc (MYL-Q)
October 4, 2016

(An update from Jerome!) (A Top Pick Feb 8/16.) Long. He covered this on Aug 25/16. This is not a name he would probably go back to.

TOP PICK
TOP PICK
February 8, 2016

Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). In a Pair trade you really have conviction on both sides. In this instance, while he likes Mylan as a Long hedge position, the conviction actually lies with Valeant as a Short, which still has a lot of fundamental problems ahead of them.

Show full opinionHide full opinion
Mylan Inc (MYL-Q)
February 8, 2016

Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). In a Pair trade you really have conviction on both sides. In this instance, while he likes Mylan as a Long hedge position, the conviction actually lies with Valeant as a Short, which still has a lot of fundamental problems ahead of them.

BUY
BUY
October 7, 2004
Recently acquired King Pharmaceuticals.
Show full opinionHide full opinion
Mylan Inc (MYL-Q)
October 7, 2004
Recently acquired King Pharmaceuticals.
Showing 1 to 9 of 9 entries
  • «
  • 1
  • »

Mylan Inc(MYL-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Mylan Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Mylan Inc(MYL-Q) Frequently Asked Questions

What is Mylan Inc stock symbol?

Mylan Inc is a American stock, trading under the symbol MYL-Q on the NASDAQ (MYL). It is usually referred to as NASDAQ:MYL or MYL-Q

Is Mylan Inc a buy or a sell?

In the last year, there was no coverage of Mylan Inc published on Stockchase.

Is Mylan Inc a good investment or a top pick?

Mylan Inc was recommended as a Top Pick by Robert Lauzon on 2017-08-10. Read the latest stock experts ratings for Mylan Inc.

Why is Mylan Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Mylan Inc worth watching?

In the last year 0 stock analysts on Stockchase covered Mylan Inc. The stock is worth watching.

What is Mylan Inc stock price?

On 2020-11-16, Mylan Inc (MYL-Q) stock closed at a price of $15.86.